OrthoPediatrics (NASDAQ:KIDS) Director Sells 18,000 Shares of Stock

Key Points

• Director David Pelizzon sold 18,000 OrthoPediatrics shares at an average price of $24.28, generating $437,040. After the sale, he retained 6.86 million shares, reducing his ownership by 0.26%.
• OrthoPediatrics reported quarterly revenue of $70.51 million and an adjusted loss of $0.26 per share, beating analyst estimates for both revenue and EPS.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $26.44; institutional investors own 69.05% of the company.

OrthoPediatrics Corp. (NASDAQ:KIDS - Get Free Report) Director David Pelizzon sold 18,000 shares of the firm's stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $24.28, for a total value of $437,040.00. Following the completion of the transaction, the director directly owned 6,863,464 shares in the company, valued at $166,644,905.92. The trade was a 0.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

OrthoPediatrics Stock Performance

OrthoPediatrics stock traded down $0.47 during trading hours on Wednesday, reaching $24.03. 169,608 shares of the company were exchanged, compared to its average volume of 171,545. OrthoPediatrics Corp. has a 12 month low of $14.42 and a 12 month high of $26.74. The company has a current ratio of 4.78, a quick ratio of 2.17 and a debt-to-equity ratio of 0.28. The stock has a 50-day moving average of $21.11 and a 200 day moving average of $18.53. The firm has a market cap of $627.42 million, a price-to-earnings ratio of -14.30 and a beta of 0.98.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.30) by $0.04. The company had revenue of $70.51 million for the quarter, compared to analyst estimates of $68.21 million. OrthoPediatrics had a negative net margin of 15.72% and a negative return on equity of 8.10%. As a group, research analysts anticipate that OrthoPediatrics Corp. will post -1.14 earnings per share for the current year.

Institutional Trading of OrthoPediatrics

A number of hedge funds have recently bought and sold shares of KIDS. BlackRock Inc. acquired a new stake in OrthoPediatrics in the 2nd quarter worth $24,347,000. Millennium Management LLC increased its holdings in shares of OrthoPediatrics by 48.0% during the 4th quarter. Millennium Management LLC now owns 1,396,495 shares of the company's stock worth $24,802,000 after purchasing an additional 452,840 shares during the period. AIGH Capital Management LLC acquired a new position in shares of OrthoPediatrics during the second quarter valued at about $5,161,000. Nantahala Capital Management LLC acquired a new position in shares of OrthoPediatrics during the second quarter valued at about $4,636,002,000. Finally, AWM Investment Company Inc. bought a new stake in shares of OrthoPediatrics in the second quarter valued at about $4,537,000. 69.05% of the stock is owned by institutional investors.

Analyst Ratings Changes

KIDS has been the subject of a number of recent analyst reports. Needham & Company LLC upped their price target on shares of OrthoPediatrics from $30.00 to $35.00 and gave the company a "buy" rating in a report on Wednesday, August 5th. Truist Financial set a $22.00 price objective on OrthoPediatrics in a research note on Wednesday, August 5th. TD Cowen reissued a "buy" rating on shares of OrthoPediatrics in a research report on Monday, June 15th. BTIG Research increased their target price on OrthoPediatrics from $24.00 to $29.00 and gave the company a "buy" rating in a research note on Thursday, August 20th. Finally, Piper Sandler restated an "overweight" rating and set a $25.00 target price (up from $22.00) on shares of OrthoPediatrics in a research note on Wednesday, August 5th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $26.44.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company's product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source